One platform across multiple screening domains
RADventure supports screening programmes across different disease areas within a single, coherent platform architecture.
Breast cancer screening
RADventure supports organised breast cancer screening programmes with platforms covering invitation, imaging workflows, reporting, and follow-up. The iBOB system supports the Dutch National Breast Cancer Screening Programme, inviting over 1.1 million women per year with approximately 80 percent attendance. RADventure has also supported the MammoXL environment for sharing mammography images and reports across major Dutch hospitals, and implemented breast screening systems in Aruba, Curaçao, and the Canary Islands, enabling paperless end-to-end workflows.
Lung cancer screening
RADventure supports population-based lung cancer screening through Nelson+, enabling risk assessment, imaging workflows, AI integration, reporting, follow-up, and programme oversight in live clinical environments. Nelson+ provides end-to-end workflow management from invitation and risk assessment through to CT imaging, reporting, and outcomes tracking, and is designed for regional and national-scale deployment.
Clinical and population-based research
RADventure supports large-scale population-based research studies and emerging screening technologies by providing secure, auditable platforms for cohort selection, invitations, randomisation, and outcome tracking. Experience includes the ROBINSCA cardiovascular risk stratification study, the PROHTECT trial offering HPV self-sampling to screening non-responders, and the Dutch Chlamydia population screening programme, which invited approximately 600,000 participants using personalised portals and digital communications.
Cervical cancer screening
RADventure has designed and operated cervical cancer screening platforms in the Netherlands since the late 1990s, supporting large-scale organised screening programmes. The CIS (Cervix Information System) has supported the Dutch National Screening Programme since 1999, administering more than six million women over time. Earlier regional systems such as CERIS (1998–2011) were migrated into CIS. RADventure systems support call–recall, results tracking, treatment follow-up, registry synchronisation, and integration for HPV-based screening and self-sampling initiatives.
Colorectal cancer screening
RADventure provides end-to-end platform support for population-based colorectal cancer screening programmes, including invitation, test logistics, laboratory coordination, results handling, follow-up, and programme monitoring. Experience includes the Corero I and II trials evaluating gFOBT, FIT, and repeat FIT screening, the iColon 3 and iColon 4 trials comparing FIT strategies and participation behaviour, and the COCOS trial assessing colonoscopy versus CT-colonography screening. RADventure supported participant management, laboratory interfaces, reporting, and audit-ready data capture across these programmes.
Prostate and emerging screening programmes
RADventure supports prostate cancer screening within its multi-domain screening platform architecture, drawing on long-standing experience in delivering large-scale, organised cancer screening programmes. The platform provides configurable workflows for participant identification, invitation, risk assessment, test coordination, results management, and follow-up, and is designed to support pilot prostate screening initiatives as well as future population-level roll-out. This approach enables prostate cancer screening to be delivered using the same governance, auditability, and clinical safety principles proven across breast, cervical, colorectal, and lung cancer screening programmes.